Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Mar 19;11(3):552.
doi: 10.3390/diagnostics11030552.

Diagnostic Role of 18F-PSMA-1007 PET/CT in Prostate Cancer Staging: A Systematic Review

Salam Awenat  1 , Arnoldo Piccardo  2 , Patricia Carvoeiras  3 , Giovanni Signore  4 , Luca Giovanella  5   6 , John O Prior  7   8 , Giorgio Treglia  5   7   8   9   10
Affiliations
Review

Diagnostic Role of 18F-PSMA-1007 PET/CT in Prostate Cancer Staging: A Systematic Review

Salam Awenat et al. Diagnostics (Basel). .

Abstract

Background: The use of prostate-specific membrane antigen (PSMA)-targeted agents for staging prostate cancer (PCa) patients using positron emission tomography/computed tomography (PET/CT) is increasing worldwide. We performed a systematic review on the role of 18F-PSMA-1007 PET/CT in PCa staging to provide evidence-based data in this setting.

Methods: A comprehensive computer literature search of PubMed/MEDLINE and Cochrane Library databases for studies using 18F-PSMA-1007 PET/CT in PCa staging was performed until 31 December 2020. Eligible articles were selected and relevant information was extracted from the original articles by two authors independently.

Results: Eight articles (369 patients) evaluating the role of 18F-PSMA-1007 PET/CT in PCa staging were selected. These studies were quite heterogeneous, but, overall, they demonstrated a good diagnostic accuracy of 18F-PSMA-1007 PET/CT in detecting PCa lesions at staging. Overall, higher primary PCa aggressiveness was associated with higher 18F-PSMA-1007 uptake. When compared with other radiological and scintigraphic imaging methods, 18F-PSMA-1007 PET/CT had superior sensitivity in detecting metastatic disease and the highest inter-reader agreement. 18F-PSMA-1007 PET/CT showed similar results in terms of diagnostic accuracy for PCa staging compared with PET/CT with other PSMA-targeted tracers. Dual imaging with multi-parametric magnetic resonance imaging and 18F-PSMA-1007 PET/CT may improve staging of primary PCa. Notably, 18F-PSMA-1007-PET/CT may detect metastatic disease in a significant number of patients with negative standard imaging.

Conclusions: 18F-PSMA-1007 PET/CT demonstrated a good accuracy in PCa staging, with similar results compared with other PSMA-targeted radiopharmaceuticals. This method could substitute bone scintigraphy and conventional abdominal imaging for PCa staging. Prospective multicentric studies are needed to confirm these findings.

Keywords: PET; PSMA; PSMA-1007; prostate cancer; staging; systematic review.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Flow chart of the search for eligible studies on the diagnostic role of 18F-PSMA-1007 positron emission tomography/computed tomography (PET/CT) in prostate cancer staging. PSMA, prostate-specific membrane antigen.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Hassanipour-Azgomi S., Mohammadian-Hafshejani A., Ghoncheh M., Towhidi F., Jamehshorani S., Salehiniya H. Incidence and mortality of prostate cancer and their relationship with the Human Development Index worldwide. Prostate Int. 2016;4:118–124. doi: 10.1016/j.prnil.2016.07.001. - DOI - PMC - PubMed
    1. Schiavina R., Chessa F., Borghesi M., Gaudiano C., Bianchi L., Corcioni B., Castellucci P., Ceci F., Ceravolo I., Barchetti G., et al. State-of-the-art imaging techniques in the management of preoperative staging and re-staging of prostate cancer. Int. J. Urol. 2018;26:18–30. doi: 10.1111/iju.13797. - DOI - PubMed
    1. Fanti S., Minozzi S., Antoch G., Banks I., Briganti A., Carrio I., Chiti A., Clarke N., Eiber M., De Bono J., et al. Consensus on molecular imaging and theranostics in prostate cancer. Lancet Oncol. 2018;19:e696–e708. doi: 10.1016/S1470-2045(18)30604-1. - DOI - PubMed
    1. Annunziata S., Pizzuto D.A., Treglia G. Diagnostic Performance of PET Imaging Using Different Radiopharmaceuticals in Prostate Cancer According to Published Meta-Analyses. Cancers. 2020;12:2153. doi: 10.3390/cancers12082153. - DOI - PMC - PubMed
    1. Okarvi S.M. Recent developments of prostate-specific membrane antigen (PSMA)-specific radiopharmaceuticals for precise imaging and therapy of prostate cancer: An overview. Clin. Transl. Imaging. 2019;7:189–208. doi: 10.1007/s40336-019-00326-3. - DOI

LinkOut - more resources